Development
Ocular Therapeutix, Inc.
OCUL
$8.19
-$0.14-1.68%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -80.74M | -67.06M | -90.73M | -88.81M | -71.04M |
| Total Depreciation and Amortization | 2.98M | 2.52M | 2.14M | 2.04M | 2.11M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.93M | 2.80M | 23.72M | 21.90M | 7.98M |
| Change in Net Operating Assets | -7.41M | -2.99M | -5.30M | 3.90M | 1.35M |
| Cash from Operations | -70.23M | -64.74M | -70.18M | -60.98M | -59.60M |
| Capital Expenditure | -6.09M | -7.78M | -8.31M | -6.82M | -3.72M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -6.09M | -7.78M | -8.31M | -6.82M | -3.72M |
| Total Debt Issued | 84.47M | 84.47M | 2.00M | 2.00M | -- |
| Total Debt Repaid | -28.13M | -28.13M | -2.00M | -2.00M | -- |
| Issuance of Common Stock | 118.66M | 10.95M | 10.56M | 1.40M | 1.45M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.18M | -5.18M | -- | -- | -- |
| Cash from Financing | 169.83M | 62.12M | 10.56M | 1.40M | 1.45M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.51M | -10.40M | -67.93M | -66.39M | -61.86M |